(Adnkronos) - “Finalmente disponibile anche in Italia pirtobrutinib, nuova terapia indicata per il trattamento di pazienti adulti con linfoma mantellare. Per assicurare l'accesso alla terapia innovativa ai pazienti è fondamentale la collaborazione con associazioni dei pazienti, medici e istituzioni” ha detto Elias Khalil, presidente e amministratore delegato Lilly Italy Hub durante la conferenza stampa, a Roma, sulle novità per i trattamenti della patologia oncoematologica.
Category
🗞
NewsTranscript
00:00Lili is deeply committed to improving the lives of patients in various therapeutic areas.
00:10We have been doing this for 150 years.
00:13In the oncology area, we have been doing research and development for about 50 years
00:21and today we are very happy to be able to start a new chapter in the area of hematology.
00:29Patients in hematology are trying to have more time to live their lives.
00:34In the last 10 years, we have seen a development of new therapies and new solutions
00:44to improve the lives of patients.
00:46For this reason, we are also committed to finding solutions for these patients
00:52who are looking for time, time to be with their families, time to live their lives.
00:58We are very proud to be able to announce that PIR2 Brutnip will be available to patients in Italy.
01:06We are working to ensure the access of this innovation to patients.
01:13For this reason, collaboration is very important,
01:18because we have to work with patient associations, doctors, clinicians and institutions
01:25to make it available to patients who are looking for this innovation.